Per‐Ola Andersson

2.8k total citations · 1 hit paper
72 papers, 2.1k citations indexed

About

Per‐Ola Andersson is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Per‐Ola Andersson has authored 72 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 21 papers in Hematology. Recurrent topics in Per‐Ola Andersson's work include Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (10 papers). Per‐Ola Andersson is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Chronic Lymphocytic Leukemia Research (17 papers) and Viral-associated cancers and disorders (10 papers). Per‐Ola Andersson collaborates with scholars based in Sweden, United States and Germany. Per‐Ola Andersson's co-authors include Hans Wadenvik, Stefan Jacobsson, Bob Olsson, Lena Carlsson, Margareta Jernås, Björn Carlsson, Sverker Hasselblom, Herman Nilsson‐Ehle, Börje Ridell and Ulrika Hansson and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Per‐Ola Andersson

71 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura

2003 519 citations Bob Olsson, Per‐Ola Andersson et al. profile →

Peers

Countries citing papers authored by Per‐Ola Andersson

Since Specialization

Citations

This map shows the geographic impact of Per‐Ola Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per‐Ola Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per‐Ola Andersson more than expected).

Fields of papers citing papers by Per‐Ola Andersson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per‐Ola Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per‐Ola Andersson. The network helps show where Per‐Ola Andersson may publish in the future.

Co-authorship network of co-authors of Per‐Ola Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of Per‐Ola Andersson. A scholar is included among the top collaborators of Per‐Ola Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Per‐Ola Andersson. Per‐Ola Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Immunity Against Tetanus and Diphtheria after Vaccination of Allogeneic Stem Cell Transplantation Recipients 2023 ·Transplantation and Cellular Therapy ·Sigrun Einarsdottir, (unknown), Krista Vaht, Tomas Bergström, Mats Brune, Per‐Ola Andersson, Christine Wennerås, Per Ljungman	2
2	Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients 2022 ·British Journal of Haematology ·(unknown), Sandra Eloranta, Sara Ekberg, Gunilla Enblad, Tarec Christoffer El‐Galaly, Birgitta Sander, Kristina Sonnevi, Per‐Ola Andersson, Mats Jerkeman, Karin E. Smedby	20
3	Artificial Intelligence Increases the Agreement among Physicians Classifying Focal Skeleton/Bone Marrow Uptake in Hodgkin’s Lymphoma Patients Staged with [18F]FDG PET/CT—a Retrospective Study 2022 ·Nuclear Medicine and Molecular Imaging ·May Sadik, (unknown), Johannes Ulén, Olof Enqvist, Per‐Ola Andersson, Rajender Kumar, Elin Trägårdh	4
4	Myocardial infarction in diffuse large B‐cell lymphoma patients – a population‐based matched cohort study 2021 ·Journal of Internal Medicine ·Sara Ekberg, (unknown), Tomas Jernberg, Karolina Szummer, Per‐Ola Andersson, Mats Jerkeman, Karin E. Smedby, Sandra Eloranta	10
5	Serum metabolomic profiling correlated with ISS and clinical outcome for multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation 2021 ·Experimental Hematology ·Ljupco Veskovski, Per‐Ola Andersson, Ingemar Turesson, Daniel Malmodin, Anders Pedersen, Ulf‐Henrik Mellqvist	7
6	Outcome and determinants of failure to complete primary R‐CHOP treatment for reasons other than non‐response among patients with diffuse large B‐cell lymphoma 2020 ·American Journal of Hematology ·Tove Wästerlid, (unknown), Therése Andersson, Sara Ekberg, Gunilla Enblad, Per‐Ola Andersson, Mats Jerkeman, Sandra Eloranta, Karin E. Smedby	12
7	Long‐term survival and loss in expectancy of life in a population‐based cohort of 7114 patients with diffuse large B‐cell lymphoma 2018 ·American Journal of Hematology ·Sara Ekberg, Mats Jerkeman, Per‐Ola Andersson, Gunilla Enblad, Björn E. Wahlin, Sverker Hasselblom, Therése Andersson, Sandra Eloranta, Karin E. Smedby	19
8	First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013 2018 ·Haematologica ·(unknown), (unknown), Hemming Johansson, Jenny Klintman, (unknown), (unknown), Eva Kimby, Stefan Norin, Per‐Ola Andersson, Claes Karlsson, Karin Karlsson, Birgitta Lauri, Mattias Mattsson, Anna Sandstedt, Maria Strandberg, Anders Österborg, Lotta Hansson	28
9	HIGH-SENSITIVITY TROPONINS AND OUTCOMES AFTER MYOCARDIAL INFARCTION 2018 ·Journal of the American College of Cardiology ·Martin J. Holzmann, (unknown), Per‐Ola Andersson, Hans Tygesen, Kai M. Eggers	1
10	Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program 2017 ·Blood ·(unknown), Per‐Ola Andersson, (unknown), Karin Karlsson, Claes Karlsson, Birgitta Lauri, Jeanette Lundin, Mattias Mattsson, Stefan Norin, Anna Sandstedt, Lotta Hansson, Anders Österborg	2
11	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL 2016 ·Clinical Epigenetics ·Santhilal Subhash, Per‐Ola Andersson, Subazini Thankaswamy Kosalai, Chandrasekhar Kanduri, Meena Kanduri	41
12	Severe infusion-related reactions are uncommon in rituximab-treated CLL patients in clinical practice: Results from a Swedish national observational study 2014 ·Leukemia Research ·Stefan Norin, Bo Björkstrand, (unknown), (unknown), Per‐Ola Andersson, (unknown), (unknown), Lotta Hansson	4
13	Tumour‐loaded α‐type 1‐polarized Dendritic Cells from Patients with Chronic Lymphocytic Leukaemia Produce a Superior NK‐, NKT‐ and CD8⁺ T Cell‐attracting Chemokine Profile 2011 ·Scandinavian Journal of Immunology ·Karin Gustafsson, Katarina Junevik, (unknown), (unknown), Alex Karlsson‐Parra, Per‐Ola Andersson	22
14	The number of tumour‐infiltrating TIA‐1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B‐cell lymphoma 2007 ·British Journal of Haematology ·Sverker Hasselblom, (unknown), Ulrika Hansson, Herman Nilsson‐Ehle, Börje Ridell, Per‐Ola Andersson	58
15	The expression of NK cell inhibitory receptors on cytotoxic T cells in B-cell chronic lymphocytic leukaemia (B-CLL) 2006 ·Annals of Hematology ·Katarina Junevik, (unknown), Sverker Hasselblom, Stefan Jacobsson, Herman Nilsson‐Ehle, Per‐Ola Andersson	9
16	Chronic idiopathic thrombocytopenic purpura (ITP): molecular mechanisms and implications for therapy 2004 ·Expert Reviews in Molecular Medicine ·Per‐Ola Andersson, Hans Wadenvik	23
17	Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura 2004 ·Thrombosis and Haemostasis ·Per‐Ola Andersson, Stefan Jacobsson, Lena Carlsson, Hans Wadenvik, Bob Olsson	57
18	Trofosfamide as Salvage Therapy for Anaplastic Large Cell Lymphoma Relapsing After High-dose Chemotherapy 2002 ·Leukemia & lymphoma ·Per‐Ola Andersson, (unknown), Herman Nilsson‐Ehle	8
19	Serum from patients with chronic idiopathic thrombocytopenic purpura frequently affect the platelet function 2002 ·Thrombosis Research ·Anna Olsson, Per‐Ola Andersson, Lilian Tengborn, Hans Wadenvik	20
20	Reduced transforming growth factor‐β1 production by mononuclear cells from patients with active chronic idiopathic thrombocytopenic purpura 2002 ·British Journal of Haematology ·Per‐Ola Andersson, Anna Olsson, Hans Wadenvik	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact